Clinical Trial Update: Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)

View source ↗

Summary

The NHLBI-sponsored clinical trial evaluating intravenous ACP-501 (rhLCAT) for familial LCAT deficiency has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Lcat Deficiency

Drugs mentioned

• ACP-501 (rhLCAT) (recombinant human lecithin-cholesterol acyltransferase)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Familial LCAT Deficiency | Status: COMPLETED